ClinicalTrials.gg
CompletedNCT02459418Updated Jun 29, 2018Results posted

Comparative Pharmacokinetics of AFOLIA and US Gonal-f® RFF Redi-ject After Single Subcutaneous Application

A Phase 1 interventional study of Afolia and US Gonal-f® in Healthy Volunteers, sponsored by Fertility Biotech AG. Completed at 1 site in United Kingdom. Open to female participants aged 18 Years to 42 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-29.

Sponsored by Fertility Biotech AG · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 42 Years
Sex
Female
01

Study summary

Comparative PK study after single SC application of Afolia and the reference product (US Gonal-f®). Objective: To demonstrate equivalence within 80%-125% margin of the reference product for the area under the curve (AUC) of Afolia.

Read the detailed description

To demonstrate equivalence within the 80% to 125% margin of the reference product for the baseline corrected area under the follicle-stimulating hormone (FSH) serum concentration-time curve from time zero to the last quantifiable concentration of AFOLIA compared to the reference product (United States [US] Gonal-f® RFF)

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Afolia
  • Follitropin
03

In context

Lead sponsor

Fertility Biotech AG is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy female volunteers aged 18 to 42 years (inclusive) with a of 18.0 to 32.0 kg/m2 (inclusive)
  2. Subjects who have used oral for at least 3 months before study entry and are prepared to stop taking oral contraception from screening and to use effective non-hormonal methods of birth control until completion of 1 menstrual cycle after the last dose administration
  3. Women of child bearing potential must agree to use effective non-hormonal contraception for birth control until completion of 1 menstrual cycle after the last dose administration
  4. Subjects with a regular menstruation cycle (25 to 34 days) before initiation of oral contraception
  5. Subjects with both ovaries
  6. Subjects who are negative for drugs of abuse and alcohol tests at screening and each admission
  7. Subjects who are healthy as determined by pre study medical history, physical examination and 12-Lead (ECG)
  8. Subjects whose clinical laboratory test results are not and are acceptable to the investigator
  9. Subjects who are able and willing to give written

Exclusion criteria

Exclusion Criteria:

  1. Subjects who do not conform to the above inclusion criteria
  2. Subjects with polycystic ovary syndrome
  3. Subjects with developing follicles or solid ovarian cysts >2 cm or complex cysts regardless of size
  4. Subjects with a history of to FSH (Ovary Hyperstimulation Syndrome)
  5. Subjects with impaired thyroid function (treated or untreated)
  6. Subjects with a history of malignant disease
  7. Subjects with and/or alanine aminotransferase >2 x reference range
  8. Subjects with other findings (, blood pressure, physical, laboratory examination)
  9. Subjects with a smoking history of more than 5 cigarettes per day
  10. Subjects with evidence of abuse of drugs or alcoholic beverages
  11. Subjects with a positive screen for surface antigen, antibodies to the virus or antibodies to the 1/2
  12. Subjects who have participated in a clinical trial within the 3 months prior to this study
  13. Subjects who are unlikely to co-operate with the requirements of the study
  14. Subjects with symptoms of a clinically relevant illness during the 3 weeks prior to study day -1
  15. Subjects who are pregnant, lactating or attempting to become pregnant
  16. Subjects with any medical condition (including a known predisposition to porphyria) that, in the opinion of the investigator, could interfere with safety of the subject or interfere with the objectives of the study
  17. Subjects who are vegans or have medical dietary restrictions
  18. Subjects who cannot communicate reliably with the investigator
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Afolia - US Gonal-f® (Sequence A) Arm

    During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive treatment sequence: (Sequence A): Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.

    Drug: Afolia · Drug: US Gonal-f®

  • Active comparator
    US Gonal-f® - Afolia (Sequence B) Arm:

    During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive treatment sequence (Sequence B): Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27

    Drug: Afolia · Drug: US Gonal-f®

Interventions

  • DrugAfolia

    During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences: Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27. Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27

    Also known as: Follitropin Alfa

  • During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences: Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27. Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27

    Also known as: Follitropin Alfa

06

What researchers measure

Primary outcomes

  1. Baseline Corrected FSH Area Under the Serum Concentration-time Curve From Zero to the Last Quantifiable Measurement [AUC(0-last)]

    AUC(0-last) was estimated for baseline corrected FSH in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean baseline corrected FSH exposure results are presented for all subjects who received active study drug and had at least 1 measured and valid concentration at a scheduled PK time point after administration of AFOLIA or Gonal-f® RFF.

    Time frame: From 0 (predose),0.5, 1, 3, 6, 9, 12, 16, 20, 21, 22, 23, 24, 25, 26, 27, 28, 48, 72, 96, 120, 144, 168 and 192 hours postdose.

  2. Baseline Corrected FSH Maximum Serum Concentration (Cmax)

    Cmax was estimated for baseline corrected FSH in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean baseline corrected FSH exposure results are presented for all subjects who received active study drug and had at least 1 measured and valid concentration at a scheduled PK time point after administration of AFOLIA or Gonal-f® RFF.

    Time frame: From 0 hours (predose) to 192 hours postdose.

Secondary outcomes

  1. Baseline Corrected FSH Area Under the Serum Concentration-time Curve Extrapolated to Infinity [AUC(0-∞)]

    AUC(0-∞) was estimated for baseline corrected FSH in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean baseline corrected FSH exposure results are presented for all subjects who received active study drug and had at least 1 measured and valid concentration at a scheduled PK time point after administration of AFOLIA or Gonal-f® RFF.

    Time frame: From 0 hours (predose) to 192 hours postdose.

  2. Baseline Corrected Time to Reach Maximum FSH Serum Concentration (Tmax)

    Tmax was estimated for baseline corrected FSH in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean was not calculated for Tmax and the non-transformed results are presented are for all subjects who received active study drug and had Tmax estimated in both periods.

    Time frame: From 0 hours (predose) to 192 hours postdose.

  3. Baseline Corrected FSH Apparent Terminal Half-life

    Apparent terminal half-life was defined as ln2/apparent terminal rate constant (λz). λz is determined by linear regression of the terminal points of the log-linear concentration-time curve. Visual assessment was used to identify the terminal linear phase of the baseline corrected concentration-time profile. A minimum of 3 data points was used for determination. Terminal half-life was estimated for baseline corrected FSH in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean baseline corrected FSH exposure results are presented for all subjects who received active study drug and had at least 1 measured and valid concentration at a scheduled PK time point after administration of AFOLIA or Gonal-f® RFF.

    Time frame: From 0 hours (predose) to 192 hours postdose.

  4. Baseline Corrected 17ß-Estrodiol (E2) Serum Exposure AUC(0-last)

    AUC(0-last) was estimated for baseline corrected E2 in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean baseline corrected E2 exposure results are presented for all subjects who received active study drug and had at least 1 measured and valid concentration at a scheduled PD time point after administration of AFOLIA or Gonal-f® RFF.

    Time frame: From 0 hours (predose) to 192 hours postdose.

  5. Baseline Corrected E2 Cmax

    Cmax was estimated for baseline corrected E2 in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean baseline corrected E2 exposure results are presented for all subjects who received active study drug and had at least 1 measured and valid concentration at a scheduled PD time point after administration of AFOLIA or Gonal-f® RFF.

    Time frame: From 0 hours (predose) to 192 hours postdose.

  6. Baseline Corrected E2 Tmax

    Tmax was estimated for baseline corrected E2 in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean was not calculated for Tmax and the non-transformed results are presented are for all subjects who received active study drug and had Tmax estimated in both periods.

    Time frame: From 0 hours (predose) to 192 hours postdose.

07

Results

Posted May 29, 2018
Limitations and caveats
None reported

Participant flow

This was a Phase 1, randomised, open label, 2-period, 2-treatment, crossover study in healthy female subjects. 42 subjects were randomised to receive either AFOLIA on study day 1 and Gonal-f® RFF on study day 27 or Gonal-f® RFF on study day 1 and AFOLIA on study day 27.

Participant flow — Overall Study
MilestoneAFOLIA Then Gonal-f® RFFGonal-f® RFF Then AFOLIA
Started2121
Received first treatment2121
Received second treatment1315
Completed1315
Not completed86
Withdrew: Exclusion criteria40
Withdrew: Protocol violation02
Withdrew: Physician decision02
Withdrew: Endometrial thickness of >5 mm10
Withdrew: Adverse event01
Withdrew: Withdrawal by subject11
Withdrew: Elevated creatine kinase10
Withdrew: Abnormal transvaginal ultrasound10

Outcome measures

PrimaryBaseline Corrected FSH Area Under the Serum Concentration-time Curve From Zero to the Last Quantifiable Measurement [AUC(0-last)]

AUC(0-last) was estimated for baseline corrected FSH in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean baseline corrected FSH exposure results are presented for all subjects who received active study drug and had at least 1 measured and valid concentration at a scheduled PK time point after administration of AFOLIA or Gonal-f® RFF.

Time frame:
From 0 (predose),0.5, 1, 3, 6, 9, 12, 16, 20, 21, 22, 23, 24, 25, 26, 27, 28, 48, 72, 96, 120, 144, 168 and 192 hours postdose.
Reported as:
Geometric mean · nanograms*hours/mL (ng*h/mL)
Baseline Corrected FSH Area Under the Serum Concentration-time Curve From Zero to the Last Quantifiable Measurement [AUC(0-last)]
nanograms*hours/mL (ng*h/mL)AFOLIAGonal-f® RFF
Baseline Corrected FSH Area Under the Serum Concentration-time Curve From Zero to the Last Quantifiable Measurement [AUC(0-last)]18.96 (2.2 to 73.2)10.47 (0.288 to 42.8)
Statistical analysis
  • AFOLIA vs Gonal-f® RFF · Geometric ls mean ratio: 164.96 · 90% CI 137.82 to 197.45
PrimaryBaseline Corrected FSH Maximum Serum Concentration (Cmax)

Cmax was estimated for baseline corrected FSH in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean baseline corrected FSH exposure results are presented for all subjects who received active study drug and had at least 1 measured and valid concentration at a scheduled PK time point after administration of AFOLIA or Gonal-f® RFF.

Time frame:
From 0 hours (predose) to 192 hours postdose.
Reported as:
Geometric mean · ng/mL
Baseline Corrected FSH Maximum Serum Concentration (Cmax)
ng/mLAFOLIAGonal-f® RFF
Baseline Corrected FSH Maximum Serum Concentration (Cmax)0.4795 (0.21 to 1.13)0.3692 (0.048 to 1.17)
Statistical analysis
  • AFOLIA vs Gonal-f® RFF · Geometric ls mean ratio: 123.15 · 90% CI 108.12 to 140.28
SecondaryBaseline Corrected FSH Area Under the Serum Concentration-time Curve Extrapolated to Infinity [AUC(0-∞)]

AUC(0-∞) was estimated for baseline corrected FSH in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean baseline corrected FSH exposure results are presented for all subjects who received active study drug and had at least 1 measured and valid concentration at a scheduled PK time point after administration of AFOLIA or Gonal-f® RFF.

Time frame:
From 0 hours (predose) to 192 hours postdose.
Reported as:
Geometric mean · ng*h/mL
Baseline Corrected FSH Area Under the Serum Concentration-time Curve Extrapolated to Infinity [AUC(0-∞)]
ng*h/mLAFOLIAGonal-f® RFF
Baseline Corrected FSH Area Under the Serum Concentration-time Curve Extrapolated to Infinity [AUC(0-∞)]27.88 (10.8 to 76)20.57 (6.43 to 49)
Statistical analysis
  • AFOLIA vs Gonal-f® RFF · Geometric ls mean ratio: 133.68 · 90% CI 102.42 to 174.49
SecondaryBaseline Corrected Time to Reach Maximum FSH Serum Concentration (Tmax)

Tmax was estimated for baseline corrected FSH in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean was not calculated for Tmax and the non-transformed results are presented are for all subjects who received active study drug and had Tmax estimated in both periods.

Time frame:
From 0 hours (predose) to 192 hours postdose.
Reported as:
Median · hours
Baseline Corrected Time to Reach Maximum FSH Serum Concentration (Tmax)
hoursAFOLIAGonal-f® RFF
Baseline Corrected Time to Reach Maximum FSH Serum Concentration (Tmax)24.05 (6 to 28.03)16 (3 to 28.08)
Statistical analysis
  • AFOLIA vs Gonal-f® RFF · Median difference (net): 7.5 · 90% CI 4.5 to 11.5
SecondaryBaseline Corrected FSH Apparent Terminal Half-life

Apparent terminal half-life was defined as ln2/apparent terminal rate constant (λz). λz is determined by linear regression of the terminal points of the log-linear concentration-time curve. Visual assessment was used to identify the terminal linear phase of the baseline corrected concentration-time profile. A minimum of 3 data points was used for determination. Terminal half-life was estimated for baseline corrected FSH in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean baseline corrected FSH exposure results are presented for all subjects who received active study drug and had at least 1 measured and valid concentration at a scheduled PK time point after administration of AFOLIA or Gonal-f® RFF.

Time frame:
From 0 hours (predose) to 192 hours postdose.
Reported as:
Geometric mean · hours
Baseline Corrected FSH Apparent Terminal Half-life
hoursAFOLIAGonal-f® RFF
Baseline Corrected FSH Apparent Terminal Half-life20.4 (7.76 to 62)18.02 (7.37 to 61.4)
SecondaryBaseline Corrected 17ß-Estrodiol (E2) Serum Exposure AUC(0-last)

AUC(0-last) was estimated for baseline corrected E2 in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean baseline corrected E2 exposure results are presented for all subjects who received active study drug and had at least 1 measured and valid concentration at a scheduled PD time point after administration of AFOLIA or Gonal-f® RFF.

Time frame:
From 0 hours (predose) to 192 hours postdose.
Reported as:
Geometric mean · pg*h/mL
Baseline Corrected 17ß-Estrodiol (E2) Serum Exposure AUC(0-last)
pg*h/mLAFOLIAGonal-f® RFF
Baseline Corrected 17ß-Estrodiol (E2) Serum Exposure AUC(0-last)888 (12.4 to 13800)570 (7.6 to 11700)
Statistical analysis
  • AFOLIA vs Gonal-f® RFF · Geometric ls mean ratio: 163 · 90% CI 94 to 282.67
SecondaryBaseline Corrected E2 Cmax

Cmax was estimated for baseline corrected E2 in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean baseline corrected E2 exposure results are presented for all subjects who received active study drug and had at least 1 measured and valid concentration at a scheduled PD time point after administration of AFOLIA or Gonal-f® RFF.

Time frame:
From 0 hours (predose) to 192 hours postdose.
Reported as:
Geometric mean · pg/mL
Baseline Corrected E2 Cmax
pg/mLAFOLIAGonal-f® RFF
Baseline Corrected E2 Cmax28.03 (3.5 to 227.1)15.95 (0.1 to 171)
Statistical analysis
  • AFOLIA vs Gonal-f® RFF · Geometric ls mean ratio: 177.17 · 90% CI 125.65 to 249.81
SecondaryBaseline Corrected E2 Tmax

Tmax was estimated for baseline corrected E2 in serum by noncompartmental methods using actual elapsed time from dosing. Baseline corrected concentrations were determined by subtracting the baseline concentration (collected immediately prior to dosing in that period) from the postdose concentration. Geometric mean was not calculated for Tmax and the non-transformed results are presented are for all subjects who received active study drug and had Tmax estimated in both periods.

Time frame:
From 0 hours (predose) to 192 hours postdose.
Reported as:
Median · hours
Baseline Corrected E2 Tmax
hoursAFOLIAGonal-f® RFF
Baseline Corrected E2 Tmax47.92 (22 to 96)27.5 (20 to 144.5)
Statistical analysis
  • AFOLIA vs Gonal-f® RFF · Median difference (net): 2.14 · 90% CI -9.91 to 12.29

Adverse events

Collected over Treatment-emergent adverse event (TEAEs) were reported from study day 1 to study day 35.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AFOLIA0/36 (0%)0/36 (0%)21/36 (58.3%)
Gonal-f® RFF0/34 (0%)0/34 (0%)22/34 (64.7%)
Most frequent other events
Most frequent other events
EventAFOLIAGonal-f® RFF
Hot flushVascular disorders11/3611/34
HeadacheNervous system disorders4/3610/34
DizzinessNervous system disorders1/363/34
Pain in extremityMusculoskeletal and connective tissue disorders3/363/34
Seasonal allergyImmune system disorders0/362/34
Catheter site related reactionGeneral disorders0/362/34
AcneSkin and subcutaneous tissue disorders0/362/34
RhinitisInfections and infestations1/362/34
HaematomaVascular disorders2/360/34

Baseline characteristics

All subjects randomized to receive study treatment.

Age, Categorical
Age, Categorical(Participants)AFOLIA Then Gonal-f® RFFGonal-f® RFF Then AFOLIATotal
<=18 years000
Between 18 and 65 years212142
>=65 years000
Age, Continuous
Age, Continuous(years)AFOLIA Then Gonal-f® RFFGonal-f® RFF Then AFOLIATotal
Mean27.8 (18 to 39)28.1 (18 to 37)28.0 (18 to 39)
Sex: Female, Male
Sex: Female, Male(Participants)AFOLIA Then Gonal-f® RFFGonal-f® RFF Then AFOLIATotal
Female212142
Male000
08

Study locations

1 site
  • Quintiles Drug Research Unit at Guy's Hospital
    London, SE1 1YR, United Kingdom
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2015 to primary completion in May 2016, 12 months.

Results were first posted in May 2018, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2015
First posted
Jun 2, 2015
StartActual
May 7, 2015
Primary completionActual
May 19, 2016
CompletionActual
May 19, 2016
Results first posted
May 29, 2018
Last update
Jun 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02459418
Lead sponsor
Fertility Biotech AG
Responsible party
Sponsor
First posted
Jun 2, 2015
Start date
May 7, 2015
Primary completion
May 19, 2016
Completion
May 19, 2016
Results posted
May 29, 2018
Last update
Jun 29, 2018

Study contacts

Julian Jenkins, DM FRCOG
study director · Fertility Biotech AG

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion